CNS biotech My­robal­an Ther­a­peu­tics rais­es $24M Se­ries A to en­ter the clin­ic

My­robal­an Ther­a­peu­tics has raised $24 mil­lion to en­ter the clin­ic with one of its four CNS ther­a­peu­tic can­di­dates, with the goal of ei­ther re­pair­ing or restor­ing func­tions in pa­tients with neu­rode­gen­er­a­tive con­di­tions.

Neu­ro­science drug dis­cov­ery and de­vel­op­ment has been heat­ing up, with re­cent high-pro­file ap­provals, large start­up fi­nanc­ings and a pair of multi­bil­lion-dol­lar ac­qui­si­tions.

Med­ford, MA-based My­robal­an was formed in mid-2021 and is based on find­ings out of Har­vard re­searcher Zhi­gang He, and has staff in Chi­na as well as the US. It’s a re­union of sorts for CEO Jing Wang, an 18-year biotech vet­er­an who did her PhD in He’s lab in the ear­ly 2000s. The biotech’s oth­er co-founder is MIT pro­fes­sor Guop­ing Feng.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER